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Abstract
Background: Platinum-containing chemotherapy produces specific DNA damage and is used to treat several
human solid tumors. Tumors initially sensitive to platinum-based drugs frequently become resistant. Inhibition of
DNA repair is a potential strategy to enhance cisplatin effectiveness. After cisplatin treatment, a balance between
repair and apoptosis determines whether cancer cells proliferate or die. DNA-dependent protein kinase (DNA-PK)
binds to DNA double strand breaks (DSBs) through its Ku subunits and initiates non-homologous end joining.
Inhibition of DNA-PK sensitizes cancer cells to cisplatin killing. The goal of this study is to elucidate the mechanism
underlying the effects of DNA-PK on cisplatin sensitivity.
Results: Silencing the expression of the catalytic subunit of DNA-PK (DNA-PKcs) increased sensitivity to cisplatin
and decreased the appearance of gH2AX after cisplatin treatment. We purified DNA-PK by its Ku86 subunit and
identified interactors by tandem mass spectrometry before and after cisplatin treatment. The structure specific
recognition protein 1 (SSRP1), Spt16 and gH2AX appeared in the Ku86 complex 5 hours after cisplatin treatment.
SSRP1 and Spt16 form the facilitator of chromatin transcription (FACT). The cisplatin-induced association of FACT
with Ku86 and gH2AX was abrogated by DNase treatment. In living cells, SSRP1 and Ku86 were recruited at sites of
DSBs induced by laser beams. Silencing SSRP1 expression increased sensitivity to cisplatin and decreased gH2AX
appearance. However, while silencing SSRP1 in cisplatin-treated cells increased both apoptosis and necrosis,
DNA-PKcs silencing, in contrast, favored necrosis over apoptosis.
Conclusions: DNA-PK and FACT both play roles in DNA repair. Therefore both are putative targets for therapeutic
inhibition. Since DNA-PK regulates apoptosis, silencing DNA-PKcs redirects cells treated with cisplatin toward
necrosis. Silencing FACT however, allows both apoptosis and necrosis. Targeting DNA repair in cancer patients may
have different therapeutic effects depending upon the roles played by factors targeted.
Background
Platinum-containing drugs are used against many solid
tumors, are decisive in the treatment of testicular cancer
and the main therapy against ovarian cancer, the leading
cause of gynecological cancer mortality [1]. Surgery fol-
lowed by adjuvant platinum-based chemotherapy (e.g.,
cisplatin or carboplatin) is an effective strategy, but
tumors tend to re-occur and cancer returning after
initial platinum-based chemotherapy is inevitably resis-
tant to these drugs [2-4]. Platinum salts (hereafter
referred to as cisplatin) produce predominantly DNA
intra-strand cross-links between adjacent purines (1,2-
adducts) that can cause changes in DNA conformation
and affect DNA replication and/or gene transcription,
resulting in cell-cycle arrest and apoptotic cell death
[5-7]. Un-repaired intra- and inter-strand cross-links will
eventually result in double-strand DNA breaks (DSBs) at
stalled replication forks. Un-repaired cross-links and
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levels of DSBs [4]. Avoidance of DNA damage-induced
cell death by increased DNA repair is a principal
mechanism of drug resistance [8,9]. Hence, targeting
DNA repair may increase the efficacy of DNA damaging
drugs such as cisplatin [10,11]. We discovered that knock
down of either the Structure-Specific Recognition Protein
1 (SSRP1) or the catalytic subunit of the DNA-dependent
protein kinase (DNA-PKcs) sensitizes transformed cells
to cisplatin [12]. The mechanism of increased sensitivity
after depletion of SSRP1 or DNA-PKcs may involve
effects on cell proliferation, DNA repair or apoptosis.
DNA-dependent protein kinase (DNA-PK) is a serine/
t h r e o n i n ek i n a s er e q u i r e df o rn o n - h o m o l o g o u sD N A
end joining (NHEJ). During NHEJ, the Ku heterodimer,
composed of Ku70 and Ku86 proteins, recognizes and
binds DNA ends at DSBs. DNA-PKcs is recruited to the
DNA-bound Ku heterodimer to form the DNA-PK
holoenzyme. The DNA Ligase IV complex, consisting of
the catalytic subunit DNA Ligase IV and its cofactor
XRCC4, performs the ligation step of repair [13]. DNA-
PK is also involved in telomere maintenance, apoptosis
and gene transcription, although its precise roles in
these processes are not fully characterized [14-16].
The Facilitator of Chromatin Transcription (FACT) is
a heterodimer composed of Suppressor of Ty (Spt16)
and SSRP1 [17]. SSRP1 is an 87 kDa, high mobility
group (HMG) domain-containing protein that binds cis-
platin-modified DNA [5,18]. We found that cisplatin
induced the exit of DNA-PK and FACT from the
nucleolus. DNA-PK activity was necessary for cisplatin-
induced loss of nucleolar SSRP1 [12]. Thus, at some
level, the functions of FACT and DNA-PK are linked.
In this study we purified the Ku86 complex and
showed recruitment of FACT into the complex after cis-
platin treatment. FACT and DNA-PK control the
appearance of gH2AX on damaged chromatin, co-loca-
lize in vivo at the site of DNA damage and contribute
to the intrinsic resistance of cancer cells to cisplatin.
However, only DNA-PK stimulates the apoptotic
response to DNA damage.
Results
Dual role of DNA-PK in the response to cisplatin
B o t hk n o c kd o w no fD N A - P K c sb ys h R N Aa n dt h e
DNA-PK inhibitor vanillin sensitize breast cancer cells
to cisplatin [12,19]. These results suggest a role for
DNA-PK in the repair of cisplatin-induced DNA
damage. Phosphorylation of H2AX at serine 139
(gH2AX) is one of the earliest cellular responses to
DNA damage and is necessary for triggering DNA repair
[20,21]. DNA-PK is capable of phosphorylating nucleo-
somal H2AX [22]. To monitor the effect of silencing
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Figure 1 Dual role of DNA-PK in response to cisplatin.A .
Cisplatin-induced phosphorylation of H2AX is regulated by DNA-PK.
DNA-PKcs (PKcs) or control (ctr) shRNA-expressing A2780 cells were
treated with 100 μg/ml cisplatin (CIS) for 0, 1 or 2 hours (hrs). DNA-
PKcs and b-actin were analyzed in whole cell lysates by
immunoblotting. gH2AX and H2A were analyzed in chromatin
fractions (chrom). B. Levels of cisplatin-induced PARP-1 cleavage
after silencing DNA-PKcs expression in A2780 cells. DNA-PKcs, PARP-
1, and b-actin were analyzed in whole cell lysates of cells treated
with 100 μg/ml cisplatin for 0, 4 or 6 hrs by immunoblotting. C.
DNA-PK inhibition sensitizes cancer cells to cisplatin. Control and
DNA-PKcs shRNA-expressing A2780, MDA-MB-231 and HEK293T cells
were treated with increasing concentrations of cisplatin. IC50 values
at 24 hrs are shown. Results represent the mean ± s.e.m. of five
independent experiments. For comparisons of control and DNA-
PKcs depletion within cell lines, p < 0.01.
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Page 2 of 11DNA-PKcs expression on the induction of DNA repair,
we monitored the amounts of gH2AX during the first 2
hours following cisplatin treatment of human ovarian
cancer A2780 cells (Figure 1A). Immunoblotting chro-
matin fractions from cells expressing control shRNA
revealed gH2AX one hour after cisplatin treatment.
However, levels of gH2AX were reduced by 37.0% and
34.6% respectively 1 and 2 hours after treatment in cells
silenced for DNA-PKcs expression (Figure 1A). Persis-
tent phosphorylation of H2AX after silencing DNA-
PKcs is likely due to other kinases involved in DNA
damage repair [23,24].
DNA-PK also participates in the apoptotic response to
DNA damage [14]. We monitored apoptosis in A2780
cells treated with cisplatin by analysis of cleaved poly
(ADP-Ribose) polymerase 1 (PARP-1) protein levels.
Immunoblotting showed that depletion of DNA-PKcs
reduced PARP-1 cleavage in cells treated with 100 μg/
ml cisplatin as soon as 4 hours after cisplatin addition
(Figure 1B, compare lanes 3 and 4). Notably, DNA-PKcs
itself was a target for apoptosis-induced cleavage (Figure
1B, lanes 4 and 6). Similar results were obtained with
the MDA-MB-231 (human breast cancer) and HEK293T
(human embryonic kidney) cell lines expressing shRNA
against DNA-PKcs (data not shown). These results sug-
gest a role for DNA-PK in controlling the induction of
apoptosis by cisplatin.
Since DNA-PK is involved in two opposing functions,
DNA repair and apoptosis, we examined the effects of
DNA-PKcs depletion on cisplatin-induced cytotoxicity.
We treated A2780, MDA-MB-231 and HEK293T cells
expressing an shRNA directed against DNA-PKcs or a
control shRNA with cisplatin (Figure 1C). DNA-PKcs
expression was reduced by more than 75% in the
A2780, MDA-MB-231 and HEK293T cell lines (data not
shown). Cells expressing shRNA directed against DNA-
PKcs were more sensitive to cisplatin treatment than
cells expressing control shRNA with an IC50 signifi-
cantly below that of control cells (Figure 1C and Addi-
tional file 1). The concentration range of cisplatin used
in the above experiments spanned 1 to 100 μg/ml. Bro-
modeoxyuridine (BrdU) incorporation assays at each
concentration showed 100% inhibition of the S-phase
counts in all cell lines, ruling out the possibility that dif-
ferences in cell proliferation due to depletion of DNA-
PKcs influenced our results (data not shown). Monitor-
ing the inception of DNA repair and apoptosis shortly
after cisplatin treatment establishes that DNA-PKcs reg-
ulates cell survival but plays roles apparently opposite in
promoting both DNA repair and apoptosis.
DNA-dependent interaction of FACT with the Ku complex
To understand the dual role of DNA-PK in controlling
both repair and apoptosis we purified the DNA-PK
complex using tagged Ku86 as bait. We hypothesized
that changes in the composition of the Ku protein com-
plex after cisplatin treatment will provide insights into
the cellular response to cisplatin-induced DNA damage.
Nuclear extracts of HeLa S3 cells stably expressing
Ku86-Flag/HA were submitted to sequential Flag and
HA immunoprecipitations [25]. Cleaved caspase-3 and
cleaved DNA-PKcs were detected between 2 and 4
hours after the beginning of cisplatin treatment in S3
cells (Additional file 2). Therefore complexes were puri-
fied from untreated cells and 1, 2 and 4 hours after cis-
platin treatment. Silver stain of the complexes showed
Ku86 co-precipitates with stoïchiometric amounts of its
heterodimeric partner Ku70 and a number of other pro-
teins. Although noticeable changes in the subunit com-
position of the complex appeared 2 hours after cisplatin
treatment, they were more pronounced after 4 hours
(Figure 2A). In three different experiments, a polypep-
tide appeared approximately at 140 kDa in the Ku86
complex 4 hours after cisplatin treatment (see arrow,
Figure 2A). The corresponding band was excised from
t h eg e ls h o w ni nF i g u r e2 Aa n ds u b m i t t e dt ot a n d e m
mass spectrometry (MSMS) analysis. This band con-
tained, among others, a major polypeptide identified as
the FACT subunit Spt16 (Table 1).
Spt16 associates with SSRP1 to form the FACT com-
plex. SSRP1 migrates at 87 kDa and could be masked by
the large Ku86 band in Figure 2A. Spt16 and SSRP1
protein levels were analyzed in Ku86 complexes purified
before and after cisplatin. Both proteins were detected
in the complex from untreated cells and a significant
cisplatin-induced increase was observed (Figure 2B lanes
2 and 3). Levels of other Ku-associated proteins, includ-
ing WRN and RHA, remained unaffected by cisplatin,
suggesting specificity in the recruitment of FACT to the
Ku complex (Figure 2B, lanes 2 and 3).
We previously observed that the specific DNA-PK
inhibitor Nu7026 prevented cisplatin-induced loss of the
nucleolar fraction of SSRP1 [ 1 2 ] .T h e r e f o r e ,w ew o n -
dered whether the cisplatin induced recruitment of
FACT to the Ku complex could be prevented by pre-
treatment of the cells with Nu7026. Our results show
no change in the cisplatin-induced recruitment of FACT
after DNA-PK inhibition (Figure 2B, lanes 4 and 5).
Therefore, recruitment of FACT after cisplatin treat-
ment does not require the kinase activity of DNA-PK.
The overall amounts of these proteins in the nuclear
extracts used for immunoprecipitation were not affected
by cisplatin, indicating changes in the concentration of
FACT in the Ku complex were not due to changes in
the overall nuclear amounts of FACT (Figure 2B; lanes
7, 8, 9 and 10).
Heo and colleagues reported the association of FACT
and DNA-PK on nucleosomes containing H2AX [26].
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Figure 2 Cisplatin-induced recruitment of FACT to the Ku complex. A. Purification of the Ku86 complex. Tandem affinity purification for
FLAG and HA was performed on nuclear extracts from S3 or S3-Ku86-Flag/HA cells 0, 1, 2 and 4 hours (hrs) after cisplatin (CIS) treatment. The
purified complexes were resolved by 4-12% NuPAGE and visualized by silver staining. Arrows show Ku70, Ku86-Flag/HA, the band identified as
spt16 through MSMS analysis and DNA-PKcs (based on molecular weight). The molecular weight markers are indicated on the left (in kDa). B.
Association of FACT with the Ku complex. Complexes purified as in (A) before or 4 hrs after cisplatin treatment (+CIS) were immunoblotted for
the indicated proteins. Cells were pre-treated with the DNA-PK inhibitor Nu7026 as indicated. C. Cisplatin-induced association of gH2AX with the
Ku complex. Inputs are nuclear extracts (NEX) and chromatin obtained before or 4 hrs after cisplatin treatment (+CIS). Inputs and Ku86
complexes purified from the inputs were immunoblotted for the indicated proteins. D. Treatment of the Ku complex with DNase reveals DNA-
dependent interactions. Ku86 complexes were purified as in (A) 2 hrs after cisplatin treatment. The complexes immobilized on anti-HA beads
were left untreated or treated with DNase and then eluted with the HA peptide. The resulting complexes were analyzed by immunoblotting for
the indicated proteins.
Table 1 Proteins identified by LC-MS/MS of cut bands in the Ku86 complex
Protein name
1 Synonym
1 Accession
Number
1
Theoretical MW
(kDa)
1
No. of
Peptides
2
Function
3
ATP-dependent DNA helicase 2 subunit 1 Ku70 P12956 69.71 21 DNA repair
ATP-dependent DNA helicase 2 subunit 2 Ku86 P13010 82.57 20 DNA repair
FACT complex subunit SPT16
4 SPT16 Q9Y5B9 119.91 11 Nucleosome/
transcription
Werner syndrome ATP-dependent helicase WRN Q14191 162.49 7 Helicase
Lamina-associated polypeptide 2 isoform
alpha
LAP2A P42166 75.36 7 DNA binding
DNA topoisomerase 1 TOP1 P11387 90.73 1 Chromatin binding
Poly (ADP-ribose) polymerase 1 PARP-1 P09874 112.95 1 DNA binding
ATP-dependent RNA helicase DDX17 Q92841 72.37 1 Helicase
1 as in the SWISS-PROT database,
2 number of peptide obtain by LC-MSMS analysis of the unique silver stained band shown in figure 1,
3 as in the Gene
Ontology classification.
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Page 4 of 11Since FACT associated with the Ku86 complex purified
from nuclear extracts after cisplatin-induced DNA
damage (Figure 2A and 2B), we asked whether gH2AX
is present in such a complex. Four hours after cisplatin
treatment, gH2AX levels were up-regulated in nuclear
extracts and chromatin fractions prior to purification of
the Ku86 complex (Figure 2C, input panel). Similarly,
gH2AX was detected in the Ku86 complex purified from
nuclear extracts of S3-Ku86-Flag/HA cells treated with
cisplatin, but not in complexes from untreated cells
(Figure 2C; lanes 5 and 6). Analysis of chromatin frac-
tions shows enrichment of gH2AX in the Ku complex
after cisplatin (Figure 2C; lanes 7 and 8). Hence,
increased gH2AX levels in the Ku complex reflect the
overall appearance of gH2AX after cisplatin treatment.
H2AX is phosphorylated on chromatin (i.e., when part
of nucleosomes). This suggests nucleosomes issued from
chromatin fragmentation in the nuclear extracts from
cisplatin treated cells are the source of gH2AX in Ku
complexes found in the nuclear extracts.
Both DNA-PK and FACT have DNA binding proper-
ties [18,27]. Therefore, DNA-PK and FACT could inter-
act in a ternary complex with DNA. To investigate
whether the interaction between DNA-PK and FACT
w a sD N A - d e p e n d e n t ,w ea n a l y z e dt h ee f f e c t so fD N A
nuclease (DNase) treatment on the composition of the
Ku86 complex purified 2 hours after cisplatin. Although
gH2AX, SSRP1, Spt16 and DNA-PKcs were readily
detected in the un-treated Ku86 complex, the associa-
tion of these proteins with Ku86 was abolished by
DNase treatment (Figure 2D). These results suggest that
cisplatin provokes the DNA-dependent association of
DNA-PK with FACT and that DNA-PK and FACT do
not interact directly.
FACT and DNA-PK associate at sites of DNA damage in
situ
We wondered if Ku86 and FACT localize together onto
damaged DNA. Bathing cells in a solution of cisplatin
damages cellular DNA in a spatially unrestricted way and
does not allow production of damage at discrete points in
nuclei. In order to induce damage in a spatially restricted
way, we produced double strand breaks (DSBs) with a UV
laser designed for micro-dissection. A2780 cells treated
overnight with BrdU were laser-damaged. Ku86 and
SSRP1 localization were analyzed by immunofluorescence.
Sites of damage were easily seen as dark stripes cutting
through DAPI stained nuclei in cells fixed 60 minutes
after damage (Figure 3, lower panels). Both SSRP1 and
Ku86 were recruited to stripes of DSBs (Figure 3). Similar
results were obtained showing recruitment of DNA-PKcs
to DSBs (data not shown).
Ku and DNA-PKcs are effectors of NHEJ. Homolo-
gous recombination (HR)-associated proteins and
gH2AX are also recruited to stripes of DSBs. Since
gH2AX and HR-associated proteins form DNA damage-
induced foci [28], we wondered if SSRP1 and Ku86
aggregate with such foci. We produced DNA damage-
induced foci by g-irradiation or cisplatin treatment and
did not observe co-localization of SSRP1 and Ku86 with
gH2AX (Additional file 3 and 4) when gH2AX formed
foci with BRCA1 (Additional file 5). These results
demonstrate that DNA-PK and FACT are present
together on damaged DNA in living cells and suggest
that FACT may not participate in HR.
FACT does not share the dual role of DNA-PK in response
to cisplatin
DNA-PK has a dual role, participating in both repair
and apoptosis after cisplatin treatment (Figure 1).
Therefore, we investigated the role of FACT in repair
and apoptosis. We established A2780 cell lines expres-
sing shRNA against SSRP1, or control shRNA (Figure
4A, lanes 1 and 2) and analyzed gH2AX levels after cis-
platin treatment. After treatment with 100 μg/ml cispla-
tin for 1 or 2 hours gH2AX was readily detected in
chromatin of control cells (Figure 4A, lanes 3 and 5). In
DAPI DAPI
Ku86 SSRP1
merge merge
Figure 3 Ku86 and SSRP1 co-localize with DSBs. Cells were fixed
with paraformaldehyde and methanol 50 to 60 minutes after DSBs
induction using a l = 337 nm “MicroBeam” laser. The cells were
immunostained for SSRP1 or Ku86 as indicated. Nuclei were
visualized with DAPI.
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appearance of gH2AX by 86.8% and 60.0% respectively 1
and 2 hours after treatment (Figure 4A, lanes 4 and 6).
These results were consistent with the reported role of
FACT in H2AX exchange at the nucleosome [26].
Knock down of SSRP1 expression in A2780, MDA-
MB-231 and HEK293T cells increased sensitivity to cis-
platin (decreased the IC50 value) when compared to cells
expressing control shRNA (Figure 4B). These effects
could be due to SSRP1 regulation of DNA-PK activity.
However, silencing of SSRP1 expression did not prevent
the cisplatin-induced autophosphorylation of DNA-PKcs
at serine 2056 (Additional file 6A). These results rule out
t h er e g u l a t i o no fD N A - P Kk i n a s ea c t i v i t yb yF A C T .
Furthermore SSRP1 knock down did not alter protein
expression levels of Ku86, DNA-PKcs or Spt16 (Addi-
tional file 6B). It is likely SSRP1 plays a singular and
direct role in DNA repair after cisplatin-induced damage.
We then performed a comparative analysis of apopto-
sis in control and SSRP1-depleted cells after cisplatin
treatment. Higher levels of cleaved PARP-1 were
detected in SSRP1-depleted A2780 cells treated with cis-
platin (Figure 4C, lanes 4 and 6) when compared to
control cells (Figure 4C, lanes 3 and 5). Similar results
were obtained when SSRP1 knock down effects were
analyzed in the MDA-MB-231 breast cancer cells (Addi-
tional file 6C). These results contrast with DNA-PKcs
knock down shown in Figure 1B and suggest SSRP1
depletion increased the apoptotic response to cisplatin.
Regulation of apoptosis and necrosis by DNA-PK and
FACT after cisplatin
Despite the implication of DNA-PK in the execution of
apoptosis (Figure 1B), cisplatin cytotoxicity is increased
in cells with depleted DNA-PKcs (Figure 1C and Addi-
tional file 1). Cisplatin can induce apoptosis as well as
necrotic cell death [29].
Chromatin fragmentation is induced by both apoptosis
and necrosis. However, necrosis results in cell membrane
fragmentation and subsequent release of fragmented
chromatin (free nucleosomes) in the culture supernatant.
Because apoptosis does not induce fragmentation of the
cell membrane, cells must first be lysed to extract free
nucleosomes. We quantified levels of free nucleosomes
in supernatants and lysates of A2780 cells expressing
DNA-PKcs, SSRP1 or control shRNA and treated with
different concentrations of cisplatin, ranging from 1.5 to
25 μg/ml for 4 hours (Figure 5, Additional file 7). In con-
trol cells, appearance of nucleosomes in lysates after cis-
platin treatment indicated robust apoptosis with little
evidence for necrosis (Figure 5, and Additional file 7).
Depletion of DNA-PKcs reduced apoptosis after cisplatin
(p < 0.05; Figure 5A and Additional file 7A). After DNA-
PKcs depletion, necrosis became the dominant response
to cisplatin (p < 0.05; Figure 5B and Additional file 7A).
In contrast to DNA-PKcs depletion, cisplatin-induced
apoptosis was higher in cells lacking SSRP1 than in con-
trol cells (P < 0.01; Figure 5C and Additional file 7B).
Although to a lesser extent than in cells lacking DNA-
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Figure 4 R o l eo fF A C Ti nr e s p o n s et oc i s p l a t i n .A .C i s p l a t i n -
induced appearance gH2AX is SSRP1-dependent. SSRP1 or control
(ctr) shRNA-expressing A2780 cells were treated with 100 μg/ml
cisplatin for 0, 1 or 2 hrs. Using immunoblotting SSRP1 and b-actin
were detected in whole cell lysates and gH2AX and H2A in
chromatin fractions. B. FACT inhibition sensitizes cancer cells to
cisplatin. SSRP1 and control shRNA-expressing A2780, MDA-MB-231
and HEK293T cells were treated with increasing concentrations of
cisplatin. IC50 values at 24 hrs are shown. Results represent the
mean ± s.e.m. of five independent experiments. For comparisons of
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Page 6 of 11PKcs, levels of cisplatin-induced necrosis increased in
SSRP1-depleted cells when compared to control cells (P
< 0.05; Figure 5D and Additional file 7B).
Consistent with the inhibition of DNA repair, depletion
of SSRP1 increases both apoptosis and necrosis in
response to cisplatin. Because DNA-PK participates in
the initiation of apoptosis, depletion of DNA-PKcs redir-
ects cisplatin-treated cells toward necrosis. These results
explain why similar levels of cisplatin-induced cytotoxi-
city are observed after silencing DNA-PKcs or SSRP1.
In conclusion FACT participates with DNA-PK in the
DNA repair response, but FACT does not share the
apoptotic functions of DNA-PK.
Discussion
Platinum-containing drugs react with DNA to form
adducts that must be excised, and the subsequent breach
in DNA repaired, in order to avoid cell death through
apoptosis. There is both direct and circumstantial evi-
dence that proficiency in DNA repair explains in part the
sensitivity of cancers to platinum-based chemotherapy
[9,11,30]. Testicular cancers, which are very sensitive to
cisplatin, are deficient in repair, whereas other solid
tumors are more proficient in repair and less sensitive to
platinum [4]. Breast and ovarian cancer cells lacking
function of either the BRCA1 or BRCA2 susceptibility
gene products are deficient in homologous recombina-
tion and more sensitive to platinum-containing drugs
[31-33]. The excision repair cross complementation
group 1 (ERCC1) is deficient in some lung cancers, and
patients with deficient tumors are more sensitive to cis-
platin-based therapy than tumors with sufficient ERCC1
[34]. Perhaps the strongest evidence for the role of DNA
repair in resistance to cisplatin is the somatic reversion
of BRCA1 and BRCA2 mutations to DNA repair profi-
cient proteins in chemotherapy-resistant cancers, initially
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treated control and DNA-PKcs depleted cells is shown, p < 0.05. B. Regulation of cisplatin-induced apoptosis and necrosis by SSRP1. SSRP1 and
control shRNA-expressing A2780 cells were treated and analysed as in (A). Comparison between cisplatin treated control and SSRP1 depleted
cells, p < 0.01 (apoptosis) and p < 0.05 (necrosis) are shown.
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Page 7 of 11treatment-sensitive [33,35,36]. Success of cisplatin ther-
apy depends on ability of cancer cells to repair cisplatin
damage. Treatment of solid tumors partially crippled by
DNA repair deficiencies opens a therapeutic window of
opportunity. This opportunity, called synthetic lethality is
a promising strategy for treatment of cancers with DNA
repair deficiencies [8,37]. Indeed, clinical trials testing the
principle of synthetic lethality caused by BRCA1 and
BRCA2 deficiencies, using PARP-1 inhibitors are under-
way [38-40]. However, for patients without inherited
defects in DNA repair pathways, the combination of dis-
abling components of repair with genotoxic chemother-
apy is logical [41].
PARP-1, FACT and DNA-PK co-purify in the H2AX
complex suggesting a coordinated role during DNA
repair [24]. We examined the effect of the inhibition of
DNA-PK and FACT on cytotoxicity due to cisplatin.
Cisplatin cytotoxicity is enhanced by vanillin, a natural
inhibitor of DNA-PK activity [19] and by shRNA reduc-
tion of DNA-PKcs (Figure 1C, Additional file 1 and
[12]). Disabling FACT by depletion of SSRP1 also sensi-
tizes cells to cisplatin (Figure 4B, Additional file 1 and
[12]). These results corroborate the hypothesis that dis-
abling DNA repair can be combined with DNA damage
to induce synthetic lethality.
We looked more closely at DNA-PK and FACT after
cisplatin treatment. SSRP1 was identified screening a
human cDNA expression library for proteins that specifi-
cally bound cisplatin-modified DNA [5]. Additionally, we
show FACT is necessary for the full expression of gH2AX,
co-localizes with DNA-PK at the site of DNA damage and
is co-purified with Ku86 in a DNA-dependent manner.
DNA also stabilizes the association of DNA-PKcs with the
Ku heterodimer [42]. The Ku complexes containing DNA-
PKcs and FACT were purified from nuclear extracts after
cisplatin treatment. Nucleosomes are found in nuclear
extracts when chromatin fragmentation occurs (e.g. during
apoptosis). Hence, FACT probably is associated with Ku
on nucleosomes freed by DNA fragmentation during cell
apoptosis. We therefore investigated the association of
DNA-PK and FACT with damaged DNA, in living cells
prior to apoptotic fragmentation.
We spatially restricted DNA DSBs using low energy
laser light after sensitization with BrdU and found Ku86
and SSRP1 localized to DSBs (Figure 3). Ku86 and
SSRP1 presence at DSBs seems unrelated to HR since
t h e yw e r en o tr e c r u i t e dt ogH2AX/BRCA1 foci after g-
irradiation or cisplatin treatment (Additional files 3, 4
and 5). We previously showed that loss of DNA-PKcs
prevents the cisplatin-induced exit of FACT from the
nucleolus [12]. Therefore, a model of events after cispla-
tin damage includes mobilization of DNA-PK and
FACT from the nucleolus, association with damaged
chromatin, and initiation of DNA repair. Disabling these
events by inhibiting or depleting subunits of FACT and
DNA-PK complexes accentuates the cytotoxicity of cis-
platin, probably by hindering DNA repair.
Furthermore, our work suggests the possibility of cali-
brating the inhibition of DNA repair by carefully choos-
ing the molecular target. Cells with stable DNA-PKcs
knock down are more sensitive to cisplatin despite a
two-fold reduction in the level of apoptosis at each dose
of cisplatin (Figure 1 and Additional file 1 and 7). Both
apoptosis and necrosis occur in cisplatin-treated cells
[6,29]. Recent findings indicate that necrosis may be a
default cell death pathway that is unmasked when essen-
tial factors of apoptosis are inhibited [43]. We found an
increase in cisplatin-induced necrosis after knock down
of DNA-PK as well as FACT. However, only FACT
knock down was associated with both apoptosis and
necrosis (Figure 5). Thus increased sensitivity to DNA
damage after DNA-PK inhibition can be explained by an
increase in necrosis.
DNA-PK was reported necessary for the activation of
apoptosis by etoposide [44] and in mouse thymocytes
and fibroblasts, p53-dependent apoptosis induced by
ionizing irradiation is suppressed in the absence of DNA-
PK [45,46]. Hence, DNA-PK is at a central fork in cell
fate after DNA damage, including after cisplatin treat-
ment of cancer cells (Figure 5). Practically, DNA-PK is a
“drug-able” kinase and DNA-PK inhibitors might conve-
niently be combined with cisplatin chemotherapy.
Conclusions
Because of its many roles, the consequences of inhibit-
ing DNA-PK are difficult to predict when compared to
inhibition of proteins involved in simpler linear path-
ways. FACT is necessary for phosphorylation of H2AX
(Figure 4A) and likely the subsequent repair of damaged
DNA [26]. Silencing SSPR1 has no effect on activation
of DNA-PK (Additional file 6A) and stimulates apopto-
sis in cisplatin-treated cells (Figure 4C and 5B). Hence,
inhibiting FACT may have different consequences than
inhibiting DNA-PK. Future pre-clinical studies in ani-
mals will determine which target in DNA repair path-
ways opens the most promising therapeutic window in
combination with cisplatin. In conclusion, although inhi-
bition of DNA repair during cisplatin treatment is a
rational combination, depending upon the DNA repair
target chosen, the effects may be quite different.
Methods
Cell lines
Human MDA-MB-231 breast and A2780 ovarian adeno-
carcinoma cells (ATCC, Manassas, VA) were cultured in
RPMI medium containing 10% (v/v) fetal bovine serum,
penicillin and streptomycin (Invitrogen, Carlsbad, CA).
HeLa S3 (S3) cells and derivatives, HEK293T cells and
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Page 8 of 11Linx cells (Open Biosystems, Thermo Fisher Scientific,
Huntsville, AL) where cultured in DMEM containing
10% (v/v) calf serum (Invitrogen) and antibiotics.
Chemicals
Cisplatin (cis-diamminedichloro-platinum) powder
(Sigma-Aldrich, St Louis, MO) was prepared freshly in
cell culture medium. Nu7026 (Sigma) was dissolved in
DMSO and stored at -20 C.
Antibodies
Mouse monoclonal antibodies used were anti-DNA-
PKcs 18-2, anti-Ku86 111 and anti-Ku70 N3H10 (Neo-
markers/Labvision, Thermo Fisher Scientific), anti-
FLAG M2 (Sigma-Aldrich), anti-SSRP1 and anti-SPT16
(Biolegend, San Diego, CA), anti-phospho(ser139)-
H2AX clone JBW301 (Abcam, Cambridge, MA), anti-
Poly (ADP ribose) Polymerase-1 (PARP-1, BD Bios-
ciences, San Jose, CA). Rabbit antibodies were anti-
RHA, anti-WRN (Santa Cruz Biotechnology, Santa Cruz,
CA), anti-H2A (Upstate, Millipore, Billerica, MA), anti-
phospho(ser139)-H2AX (Abcam), anti-cleaved caspase-3
(Cell Signaling Technology, Danvers, MA) and anti-
DNA-PKcs phospho-serine 2056 (a kind gift from Dr. B.
Chen) [47].
Immunofluorescence analysis
Cells grown on glass coverslips were fixed with 3.7%
paraformaldehyde (PFA) and permeabilized with metha-
nol for 10 minutes. The cells were incubated with pri-
mary antibodies at a 1/300 dilution for 1 hr at 37C,
rinsed with PBS and incubated for 30 min at 37C with
secondary antibodies conjugated to Alexa Fluor-488 or
Alexa Fluor-594 fluorochromes (Molecular Probes, Invi-
trogen), at a 1/300 dilution. DNA was visualized by
DAPI (Sigma-Aldrich). Fluorochromes were visualized
with an Axioskop II microscope and imaged with Axio-
Vision 4.5 software (Zeiss, Jena, Germany).
Assays of DNA damage
Laser-induced DNA DSBs were generated using a P.A.L.
M. MicroBeam laser microdissection system (Zeiss) at l
= 337 nm as previously described [48,49]. Cells were
grown on coverslips for 24 hours in media containing
10 uM BrdU (Sigma-Aldrich) prior to laser treatment.
After laser stripe generation, cells were incubated at 37°
C and fixed 60 min later for immunofluorescence. DNA
damage-induced foci were generated either by g-irradia-
tion or cisplatin and visualized by gH2AX immunofluor-
escence [50].
Plasmids and transfection
For DNA-PKcs silencing, retroviruses were produced by
transfecting retroviral pSM2c expression vector (Open
Biosystems) containing a puromycin resistance gene and
a control shRNA (5’TCTCGCTTGGGCGAGAGTAAG)
or a shRNA to DNA-PKcs (5’GGAGCTTACATGCT
AATGTAT) into the Linx packaging cell line. On day
three, virus-containing supernatants were added to
MDA-MB-231 and A2780 cells and incubated in 5 μg/ml
polybrene. For knock down of FACT, small hairpin
sequences specific to SSRP1 (5’CACCACAGTACTGCG
TCTGTT) were cloned into the pcDNA6.2 vector (Invi-
trogen) containing a blastocidin resistance gene, accord-
ing to manufacturer instructions. A control shRNA
sequence (5’GTCTCCACGCGCACTACATTT) was used
to generate a non-silencing control plasmid. Transfection
of HEK293T, MDA-MB-231 and A2780 cells was assisted
by FuGENE HD (Roche, Indianapolis, IN). Selection with
puromycin or blastocidin started 48 hrs after transfec-
tion. After 10 days resistant colonies where expanded
and protein knock down determined by immunoblotting
and immunofluorescence.
Tandem affinity purifications
HeLa S3 cells expressing Ku86 fused to Flag and HA
tags (S3-Ku86-Flag/HA) were treated as indicated. Sub-
cellular fractions were prepared as described [51].
Briefly, cells were incubated in hypotonic buffer (10 mM
Tris-HCl [pH 8], 10 mM KCl, 1.5 mM MgCl2) on ice
for 10 min and homogenized by tight dounce. Nuclei
were collected by centrifugation at 2000 g for 15 min at
4°C and extracted with 40 mM Tris-HCl [pH 8], 200
mM NaCl, 10% glycerol, 2 mM EDTA, 0.5% NP40 and
a 1 × protease inhibitor mix for 45 min at 4°C. The
insoluble material (chromatin) was pelleted at 15,000 g
for 30 min at 4°C, and the supernatant called “nuclear
extract” (NEX). NEX or chromatin were further treated
through two sequential FLAG and HA immunoprecipi-
tations as previously described [25].
Chromatin preparation
Chromatin pellets obtained as described above were
washed in 20 mM Tris-HCL pH 7.5, 100 mM KCl, 2
mM MgCl2,a n d1m MC a C l 2 and incubated at room
temperature in 0.05 U/μl micrococcal nuclease (MNase,
Nuclease S7, Roche) for 15 min, pelleted and the super-
natant was collected.
Immunoblotting
Samples were separated on NuPAGE 4-12% gels (Invi-
trogen), analyzed by immunoblotting with the indi-
cated antibodies and visualized with Supersignal
chemi-luminescent reagents (Pierce, Thermo Fisher
Scientific) and a luminescent image analyzer LAS-
3000mini (Fujifilm, Edison, NJ). When indicated rela-
tive amounts of proteins were compared using ImageJ
software.
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Cytotoxicity was assessed by the 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfenyl)-2H-tet-
razolium, inner salt (MTS) assay using the CellTiter 96
Aqueous One Solution Proliferation Assay (Promega,
Madison, WI), according to the manufacturer’s protocol.
Cells were seeded in 96-well plates at a density of 5000
cells/well. After overnight incubation, cisplatin was
added at the concentrations indicated. The absorbance
of each well was measured at 490 nm. Values for con-
trol cells were considered as 100% viability. The dose-
response curves were plotted as a percentage absorbance
of control cells. The half maximal inhibition (IC50)
value was calculated from the percent inhibition curve
generated using Excel XLfit software (Microsoft, Red-
mond, WA).
The Cell Death Detection ELISA Assay (Roche) was
used to analyze apoptosis and necrosis in response to
cisplatin. The assay is a sandwich-enzyme-immunoassay
using antibodies directed against DNA and histones and
allowing quantification of nucleosomes. Nucleosomes
were quantified either in the cell culture supernatant
(necrosis) or in cell lysates (apoptosis). The assay was
performed as recommended by the supplier.
Statistical analysis
For the MTS and Cell Death Detection ELISA assays, all
values were expressed as mean ± s.e.m. Differences
between groups were tested for statistical significance
using Student’s paired t-test. P < 0.05 represented a sig-
nificant difference.
Additional material
Additional file 1: Silencing the expression of DNA-PKcs or SSRP1
increases cell sensitivity to cisplatin. DNA-PKcs, SSRP1 and control
shRNA-expressing A2780, MDA-MB-231 and HEK293T cells were treated
with increasing concentrations of cisplatin as indicated. Cytotoxicity was
assessed by the MTS assay.
Additional file 2: DNA-PK Regulates cisplatin-induced apoptosis.
Extracts from HeLa-S3 cells treated with 100 μg/ml cisplatin for the
indicated time were immunoblotted for DNA-PKcs, Ku86 and cleaved
caspase-3.
Additional file 3: SSRP1 does not co-localize with DNA damage-
induced gH2AX foci. A2780 cells were immunostained for SSRP1 and
gH2AX before or 4 hours after DNA damage. Nuclei were visualized with
DAPI. A. Undamaged cells. B. Gamma irradiation (10 Gray). C. Cisplatin
treatment (25 μg/ml).
Additional file 4: Ku86 does not co-localize with DNA damage-
induced gH2AX foci. A2780 cells were immunostained for Ku86 and
gH2AX before or 4 hours after DNA damage. Nuclei were visualized with
DAPI. A. Undamaged cells. B. Gamma irradiation (10 Gray). C. Cisplatin
treatment (25 μg/ml).
Additional file 5: BRCA1 co-localizes with DNA damage-induced
gH2AX foci. A2780 cells were immunostained for BRCA1 and gH2AX
before or 4 hours after DNA damage. Nuclei were visualized with DAPI.
A. Undamaged cells. B. Gamma irradiation (10 Gray). C. Cisplatin
treatment (25 μg/ml).
Additional file 6: Effects of SSRP1 depletion on DNA-PK and
apoptosis. A. DNA-PK activation after cisplatin treatment is SSRP1-
independent. DNA-PKcs was immunoprecipitated from SSRP1 and
control shRNA expressing A2780 cells treated with 100 μg/ml cisplatin
for 0, 1 and 2 hours. Immunoprecipitates were analyzed by
immunoblotting for DNA-PKcs-Ser2056 and DNA-PKcs. B. SSRP1 knock
down does not alter Ku86, Spt16 and DNA-PKcs expression. Whole cell
lysates of SSRP1 and control shRNA-expressing A2780 cells were analyzed
by immunoblotting for b-actin, Ku86, SSRP1, Spt16 and DNA-PKcs. C. Role
of FACT in cisplatin-induced apoptosis in MDA-MB-231 breast cancer
cells. Whole cell lysates of SSRP1 or control shRNA-expressing cells
treated with 100 μg/ml cisplatin for 0, 4 or 6 hrs were analyzed by
immunoblotting for indicated proteins.
Additional file 7: Regulation of cisplatin-induced apoptosis and
necrosis by DNA-PKcs and SSRP1. A. Regulation of cisplatin-induced
apoptosis and necrosis by DNA-PKcs. Free nucleosomes were quantified
in culture supernatants (necrosis) and lysates (apoptosis) of DNA-PKcs
and control shRNA-expressing A2780 cells treated with various
concentrations of cisplatin, from 1.5 to 25 μg/ml for 24 hrs. B. Regulation
of cisplatin-induced apoptosis and necrosis by SSRP1. SSRP1 and control
shRNA-expressing A2780 cells were treated with various concentrations
of cisplatin for 24 hrs. Nucleosomes were quantified as in A.
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